|
Name |
Deoxymutaaspergillic acid
|
Molecular Formula | C11H18N2O | |
IUPAC Name* |
3-(2-methylpropyl)-6-propan-2-yl-1H-pyrazin-2-one
|
|
SMILES |
CC(C)CC1=NC=C(NC1=O)C(C)C
|
|
InChI |
InChI=1S/C11H18N2O/c1-7(2)5-9-11(14)13-10(6-12-9)8(3)4/h6-8H,5H2,1-4H3,(H,13,14)
|
|
InChIKey |
VRFLYCYGTDKKKO-UHFFFAOYSA-N
|
|
Synonyms |
Deoxymutaaspergillic acid; Aflatoxin b-2'; 0C9LJ2USYB; Pyrazinol, 3-isobutyl-6-isopropyl-; 6-(1-Methylethyl)-3-(2-methylpropyl)-2(1H)-pyrazinone; 2(1H)-Pyrazinone, 6-(1-methylethyl)-3-(2-methylpropyl)-; 22318-05-4; UNII-0C9LJ2USYB; Dideoxymutaaspergillic acid; Q27896858
|
|
CAS | 22318-05-4 | |
PubChem CID | 10285858 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 194.27 | ALogp: | 1.7 |
HBD: | 1 | HBA: | 2 |
Rotatable Bonds: | 3 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 41.5 | Aromatic Rings: | 1 |
Heavy Atoms: | 14 | QED Weighted: | 0.804 |
Caco-2 Permeability: | -4.597 | MDCK Permeability: | 0.00002580 |
Pgp-inhibitor: | 0 | Pgp-substrate: | 0.002 |
Human Intestinal Absorption (HIA): | 0.021 | 20% Bioavailability (F20%): | 0.038 |
30% Bioavailability (F30%): | 0.101 |
Blood-Brain-Barrier Penetration (BBB): | 0.842 | Plasma Protein Binding (PPB): | 76.18% |
Volume Distribution (VD): | 1.148 | Fu: | 15.51% |
CYP1A2-inhibitor: | 0.441 | CYP1A2-substrate: | 0.899 |
CYP2C19-inhibitor: | 0.518 | CYP2C19-substrate: | 0.717 |
CYP2C9-inhibitor: | 0.303 | CYP2C9-substrate: | 0.935 |
CYP2D6-inhibitor: | 0.054 | CYP2D6-substrate: | 0.143 |
CYP3A4-inhibitor: | 0.039 | CYP3A4-substrate: | 0.273 |
Clearance (CL): | 6.577 | Half-life (T1/2): | 0.663 |
hERG Blockers: | 0.027 | Human Hepatotoxicity (H-HT): | 0.324 |
Drug-inuced Liver Injury (DILI): | 0.965 | AMES Toxicity: | 0.02 |
Rat Oral Acute Toxicity: | 0.636 | Maximum Recommended Daily Dose: | 0.039 |
Skin Sensitization: | 0.052 | Carcinogencity: | 0.347 |
Eye Corrosion: | 0.006 | Eye Irritation: | 0.409 |
Respiratory Toxicity: | 0.861 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC000343 | 0.463 | D0A3HB | 0.268 | ||||
ENC002473 | 0.429 | D0R1QE | 0.262 | ||||
ENC003436 | 0.310 | D03QJL | 0.258 | ||||
ENC004719 | 0.298 | D02EZM | 0.236 | ||||
ENC002212 | 0.274 | D0R2KF | 0.222 | ||||
ENC000990 | 0.274 | D0I0DS | 0.220 | ||||
ENC000187 | 0.265 | D0S5WG | 0.220 | ||||
ENC001136 | 0.259 | D04QJD | 0.220 | ||||
ENC004273 | 0.258 | D05MFA | 0.217 | ||||
ENC000470 | 0.255 | D0R6BR | 0.215 |